July 31, 2025

Medical Oddities: Bubble Tea May Brew Burnout

From bubble tea to AI triage, small inputs had big impacts on mood, and memory.

Conexiant

August 07, 2025

Allogeneic Islet Transplant Shows Promise Without Immunosuppression

First-in-human trial shows genetically engineered islet cells restore insulin secretion in type 1 diabetes without triggering immune rejection.

Conexiant

August 05, 2025

What Do Patients Look for in Health Care Facilities?

An analysis of online reviews of health care facilities identified language patterns associated with positive or negative patient experiences.

Conexiant

July 29, 2025

Elevating Sarcoma Care: Multidisciplinary Collaboration and Innovation in Rare Cancer Treatment Page Summary

Sarcomas remain one of the most diverse and challenging cancer types to diagnose and treat. Baptist Health Cancer Care continues to advance care through coordinated expertise, early detection efforts, and emerging research opportunities.

Baptist Health South Florida

July 22, 2025

Placenta Accreta Guidelines Lack Consensus: Review

A new review of clinical guidelines highlights consistent recommendations for diagnosing and managing placenta accreta spectrum disorders, but showed gaps in guidance for surgery, fertility counseling, and postnatal care, especially in low-resource settings.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant

March 28, 2025

A Portable Vision

Aston Vision Sciences’ founder, Karl Obszanski, outlines the potential of the Lumio device to expand access to eye care around the world

The Ophthalmologist